[go: up one dir, main page]

WO2015065524A3 - Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas - Google Patents

Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas Download PDF

Info

Publication number
WO2015065524A3
WO2015065524A3 PCT/US2014/038993 US2014038993W WO2015065524A3 WO 2015065524 A3 WO2015065524 A3 WO 2015065524A3 US 2014038993 W US2014038993 W US 2014038993W WO 2015065524 A3 WO2015065524 A3 WO 2015065524A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
differentiation
clustering
suspension
pluripotent stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/038993
Other languages
English (en)
Other versions
WO2015065524A2 (fr
Inventor
Benjamin Fryer
Daina LANIAUSKAS
Marcia BLACKMOORE
Haiyun Wang
Kostadinka LILOVA
Shelley Nelson
Elizabeth ROSOCHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/998,974 external-priority patent/US10377989B2/en
Priority to EP14857034.4A priority Critical patent/EP3063268A4/fr
Priority to MX2016005657A priority patent/MX2016005657A/es
Priority to JP2016527338A priority patent/JP2016534731A/ja
Priority to AU2014342995A priority patent/AU2014342995C1/en
Priority to CN201480059910.5A priority patent/CN105793413A/zh
Priority to CA2928639A priority patent/CA2928639A1/fr
Priority to KR1020187034291A priority patent/KR20180128529A/ko
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority to SG11201603045VA priority patent/SG11201603045VA/en
Priority to RU2016121409A priority patent/RU2689710C2/ru
Priority to KR1020167014409A priority patent/KR20160079072A/ko
Publication of WO2015065524A2 publication Critical patent/WO2015065524A2/fr
Publication of WO2015065524A3 publication Critical patent/WO2015065524A3/fr
Priority to PH12016500782A priority patent/PH12016500782A1/en
Anticipated expiration legal-status Critical
Priority to AU2018208707A priority patent/AU2018208707A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/19—Growth and differentiation factors [GDF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de préparation de groupes de cellules souches pluripotentes agrégés aux fins de différenciation. L'invention concerne en particulier des méthodes de différenciation de cellules souches pluripotentes en lignées de cellules béta, de cellules cardiaques et de cellules neuronales par regroupement en suspension. Les méthodes comprennent la préparation des groupes de cellules agrégés puis de la différenciation de ces agrégats.
PCT/US2014/038993 2013-11-01 2014-05-21 Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas Ceased WO2015065524A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
RU2016121409A RU2689710C2 (ru) 2013-11-01 2014-05-21 Суспендирование и кластеризация плюрипотентных стволовых клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
SG11201603045VA SG11201603045VA (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
JP2016527338A JP2016534731A (ja) 2013-11-01 2014-05-21 膵内分泌細胞への分化のためのヒト多能性幹細胞の懸濁及び集団化
AU2014342995A AU2014342995C1 (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
CN201480059910.5A CN105793413A (zh) 2013-11-01 2014-05-21 用于分化成胰腺内分泌细胞的人多能干细胞的悬浮和群集
CA2928639A CA2928639A1 (fr) 2013-11-01 2014-05-21 Mise en suspension et agregation de cellules souches pluripotentes humaines aux fins de differenciation en cellules endocrines du pancreas
KR1020187034291A KR20180128529A (ko) 2013-11-01 2014-05-21 췌장 내분비 세포로의 분화를 위한 인간 만능 줄기세포의 현탁 및 클러스터링
EP14857034.4A EP3063268A4 (fr) 2013-11-01 2014-05-21 Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas
KR1020167014409A KR20160079072A (ko) 2013-11-01 2014-05-21 췌장 내분비 세포로의 분화를 위한 인간 만능 줄기세포의 현탁 및 클러스터링
MX2016005657A MX2016005657A (es) 2013-11-01 2014-05-21 Suspensión y agrupamiento de células madre humanas pluripotentes para la diferenciación a células endocrinas pancreáticas.
PH12016500782A PH12016500782A1 (en) 2013-11-01 2016-04-27 Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
AU2018208707A AU2018208707A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361962158P 2013-11-01 2013-11-01
US61/962,158 2013-11-01
US13/998,974 US10377989B2 (en) 2012-12-31 2013-12-30 Methods for suspension cultures of human pluripotent stem cells
US13/998,974 2013-12-30

Publications (2)

Publication Number Publication Date
WO2015065524A2 WO2015065524A2 (fr) 2015-05-07
WO2015065524A3 true WO2015065524A3 (fr) 2015-08-13

Family

ID=53004904

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/038993 Ceased WO2015065524A2 (fr) 2013-11-01 2014-05-21 Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas
PCT/US2014/042796 Ceased WO2015065537A1 (fr) 2013-11-01 2014-06-17 Mise en suspension et regroupement de cellules souches pluripotentes humaines pour la différenciation en cellules endocrines pancréatiques

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2014/042796 Ceased WO2015065537A1 (fr) 2013-11-01 2014-06-17 Mise en suspension et regroupement de cellules souches pluripotentes humaines pour la différenciation en cellules endocrines pancréatiques

Country Status (12)

Country Link
EP (2) EP3063268A4 (fr)
JP (2) JP2016534731A (fr)
KR (4) KR20180128529A (fr)
CN (2) CN105793413A (fr)
AU (4) AU2014342995C1 (fr)
BR (1) BR112016009393A8 (fr)
CA (2) CA2928639A1 (fr)
MX (2) MX2016005657A (fr)
PH (2) PH12016500783A1 (fr)
RU (2) RU2689710C2 (fr)
SG (2) SG11201603045VA (fr)
WO (2) WO2015065524A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014342995C1 (en) * 2013-11-01 2018-08-09 Janssen Biotech, Inc. Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
JP7637323B2 (ja) * 2016-06-23 2025-02-28 ティソン バイオテック，インコーポレイテッド 副甲状腺ホルモン１型受容体を発現する細胞およびその使用
JP7088564B2 (ja) 2016-11-10 2022-06-21 ヴィアサイト，インコーポレイテッド 細胞送達装置におけるｐｄｘ１膵臓内胚葉細胞及びその方法
RU2758006C2 (ru) * 2016-11-16 2021-10-25 Сината Терапьютикс Лимитед Анализ плюрипотентных стволовых клеток
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
WO2019018818A1 (fr) * 2017-07-21 2019-01-24 Semma Therapeutics, Inc. Réagrégation de cellules bêta pancréatiques dérivées de cellules souches
JP7000896B2 (ja) * 2017-08-23 2022-01-19 王子ホールディングス株式会社 細胞シート形成部材、細胞シート形成部材の製造方法、および、細胞シートの製造方法
MX2020007071A (es) * 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
SG11202006731VA (en) * 2018-01-18 2020-08-28 Agency Science Tech & Res Method for differentiation of human pluripotent stem cell lines in suspension culture
KR102115360B1 (ko) * 2018-05-30 2020-05-26 주식회사 바이블리오테카 성체 줄기세포 배양액 및 그 제조방법
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
WO2020243663A1 (fr) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. Composite à membrane biocompatible
JP7328362B2 (ja) 2019-05-31 2023-08-16 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド 制御された酸素拡散距離を伴う細胞カプセル化デバイス
CN114173837A (zh) 2019-05-31 2022-03-11 W.L.戈尔及同仁股份有限公司 生物相容性膜复合材料
WO2020243666A1 (fr) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. Composite à membrane biocompatible
CN114585728A (zh) * 2019-08-27 2022-06-03 联合治疗公司 用于培养肺泡细胞的方法和组合物
BR112022004026A2 (pt) 2019-09-05 2022-08-16 Crispr Therapeutics Ag Células doadoras universais
US11116798B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
JP2023503302A (ja) * 2019-11-22 2023-01-27 ノヴォ ノルディスク アー／エス スピン凝集した神経系マイクロスフェアおよびその応用
US11566230B2 (en) 2020-12-31 2023-01-31 Crispr Therapeutics Ag Universal donor cells
US20240191185A1 (en) * 2021-03-25 2024-06-13 Kaneka Corporation Method for producing pluripotent stem cell population
CN116218766A (zh) * 2023-04-21 2023-06-06 北京意胜生物科技有限公司 一种制备胰腺前体细胞的方法、培养基及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US20130189777A1 (en) * 2011-12-22 2013-07-25 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells
US20130224156A1 (en) * 2012-02-29 2013-08-29 Riken Method of producing human retinal pigment epithelial cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453954A4 (fr) * 2001-11-09 2004-12-15 Artecel Sciences Inc Differenciation pancreatique endocrine de cellules stromales derivees du tissu adipeux et utilisation desdites cellules
US9040297B2 (en) * 2006-08-02 2015-05-26 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
JP5067949B2 (ja) * 2006-11-09 2012-11-07 独立行政法人国立国際医療研究センター 霊長類動物胚性幹細胞の培養及び継代方法、並びにその分化誘導方法
CN104250632B (zh) * 2007-07-01 2018-09-11 生命扫描有限公司 单个多能干细胞培养
EP2271747B1 (fr) * 2008-03-17 2016-09-07 Agency for Science, Technology And Research Microsupports pour culture de cellules souches pluripotentes
AU2009267137A1 (en) * 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
US8008075B2 (en) * 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
AU2010283229B2 (en) * 2009-08-12 2015-04-02 Kyoto University Method for inducing differentiation of pluripotent stem cells into neural precursor cells
EP2582795B1 (fr) * 2010-06-15 2017-04-12 Kyoto University Procédé de sélection de cellules souches pluripotentes induites humaines
PH12013500389A1 (en) * 2010-08-31 2013-04-22 Janssen Biotech Inc Differentiation of human embryonic stem cells
WO2012117333A1 (fr) * 2011-02-28 2012-09-07 Stempeutics Research Malaysia Sdn Bhd Isolement et expansion de cellules souches adultes, composition thérapeutique les comprenant et utilisations associées
US8951798B2 (en) * 2011-10-13 2015-02-10 Wisconsin Alumni Research Foundation Generation of cardiomyocytes from human pluripotent stem cells
EP2938722B1 (fr) * 2012-12-31 2021-12-08 Janssen Biotech, Inc. Mise en suspension et agrégation de cellules pluripotentes humaines pour la différenciation en cellules endocrines du pancréas
AU2014342995C1 (en) * 2013-11-01 2018-08-09 Janssen Biotech, Inc. Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US20130189777A1 (en) * 2011-12-22 2013-07-25 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells
US20130224156A1 (en) * 2012-02-29 2013-08-29 Riken Method of producing human retinal pigment epithelial cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
EGUIZABAL ET AL.: "Complete Meiosis from Human Induced Pluripotent Stem Cells.", STEM CELLS., vol. 29, no. 8, 2011, pages 1186 - 95, XP055218519 *
MINAMI ET AL.: "A Small Molecule that Promotes Cardiac Differentiation of Human Pluripotent Stem Cells under Defined, Cytokine- and Xeno-free Conditions.", CELL REP., vol. 2, no. 5, November 2012 (2012-11-01), pages 1448 - 60., XP055097336 *
NIE ET AL.: "Scalable passaging of adherent human pluripotent stem cells.", PLOS ONE., vol. 9, no. 1, 2014, pages E88012, XP055218521 *
ROWLEY ET AL.: "Meeting Lot-Size Challenges of Manufacturing Adherent Cells for Therapy.", BIOPROCESS INT., vol. 10, no. 3, March 2012 (2012-03-01), pages 16 - 22, XP055218518 *
STACPOOLE ET AL.: "Efficient derivation of neural precursor cells, spinal motor neurons and midbrain dopaminergic neurons from human ES cells at 3% oxygen.", NAT PROTOC., vol. 6, no. 8, 2011, pages 1229 - 40, XP055218516 *
VIEIRA ET AL.: "Modulation of neuronal stem cell differentiation by hypoxia and reactive oxygen species.", PROG NEUROBIOL., vol. 93, no. 3, 2011, pages 444 - 55, XP028175304 *
WANT ET AL.: "The larger scale expansion of pluripotent stem cells for regenerative medicine purposes.", LOUGHBOROUGH UNIVERSITY INSTITUTIONAL REPOSITORY, SUBMITTED FOR PUBLICATION ON REGEN MED., vol. 7, no. 1, January 2012 (2012-01-01), pages 71 - 84, XP055354028, Retrieved from the Internet <URL:https://dspace.boro.ac.uk/dspace- jspui/bitstream/2134/11041/6/HewittVersion.pdf> [retrieved on 20140826] *
YANG ET AL.: "Evaluation of human MSCs cell cycle, viability and differentiation in micromass culture.", BIORHEOLOGY., vol. 43, no. 3-4, 2006, pages 489 - 96, XP055339090, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/16912420> [retrieved on 20140917] *
ZUSCIK ET AL.: "Regulation of chondrogenesis and chondrocyte differentiation by stress.", J CLIN INVEST., vol. 118, no. 2, 2008, pages 429 - 38, XP055218520 *

Also Published As

Publication number Publication date
KR20180128529A (ko) 2018-12-03
MX2016005658A (es) 2017-01-05
EP3063269A4 (fr) 2017-07-12
PH12016500782A1 (en) 2016-06-13
KR20180130001A (ko) 2018-12-05
CN105683362A (zh) 2016-06-15
CA2928741A1 (fr) 2015-05-07
MX2016005657A (es) 2017-01-05
KR20160079072A (ko) 2016-07-05
PH12016500783A1 (en) 2016-06-13
BR112016009393A8 (pt) 2020-03-24
SG11201603047PA (en) 2016-05-30
WO2015065537A1 (fr) 2015-05-07
WO2015065524A2 (fr) 2015-05-07
RU2016121404A3 (fr) 2018-03-29
AU2018208717A1 (en) 2018-08-16
KR20160079071A (ko) 2016-07-05
EP3063268A4 (fr) 2017-11-29
JP2016534731A (ja) 2016-11-10
CN105793413A (zh) 2016-07-20
RU2016121409A3 (fr) 2018-03-29
CA2928639A1 (fr) 2015-05-07
AU2014343007C1 (en) 2018-08-09
RU2016121404A (ru) 2017-12-04
SG11201603045VA (en) 2016-05-30
AU2014342995B2 (en) 2018-04-26
AU2014342995C1 (en) 2018-08-09
JP2017500013A (ja) 2017-01-05
AU2014343007B2 (en) 2018-04-26
RU2689710C2 (ru) 2019-05-29
EP3063269A1 (fr) 2016-09-07
AU2018208707A1 (en) 2018-08-16
AU2014343007A1 (en) 2016-05-05
RU2016121409A (ru) 2017-12-04
AU2014342995A1 (en) 2016-05-05
EP3063268A2 (fr) 2016-09-07

Similar Documents

Publication Publication Date Title
WO2015065524A3 (fr) Mise en suspension et agrégation de cellules souches pluripotentes humaines aux fins de différenciation en cellules endocrines du pancréas
IL285922A (en) Interneuronal cells of the cerebral cortex and other neurons produced by direct differentiation of pluripotent and multipotent cells
HK1217727A1 (zh) 用於分化成胰腺內分泌細胞的人多能細胞的懸浮和群集
WO2014124087A8 (fr) Cellules progénitrices d&#39;oligodendrocyte issues de cellules pluripotentes induites pour le traitement de troubles de la myéline
WO2014100779A8 (fr) Procédés de production de plaquettes à partir de cellules souches pluripotentes, et compositions associées
PH12018501293A1 (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
WO2012030539A3 (fr) Différenciation de cellules souches embryonnaires humaines
WO2014153069A3 (fr) Compositions et procédés de reprogrammation de lignées de cellules souches hématopoïétiques
HK1207885A1 (en) Differentiation of human embryonic stem cells into pancreatic endoderm
EP3546568A3 (fr) Différenciation de cellules souches pluripotentes et de cellules progénitrices cardiaques en fibres de cellules myocardiques striées à l&#39;aide de laminines ln -511, ln -521 et ln -221
HK1222205A1 (zh) 由多能干细胞产生的光感受器和光感受器袓细胞
PH12014501426A1 (en) Induced pluripotent stem cells from human umbilical cord tissue-derived cells
WO2012030538A3 (fr) Différenciation de cellules souches embryonnaires humaines
WO2012092049A3 (fr) Modification des adipocytes bruns
WO2014113704A3 (fr) Amélioration de la différenciation de cellules souches mésenchymateuses
MX2016014008A (es) Metodo para diferenciacion de celulas madre pluripotentes en cardiomiocitos.
WO2015089228A3 (fr) Compositions et procédés pour produire et gérer des adipocytes bruns
SG11201900989QA (en) Method for inducing differentiation of pluripotent stem cells in vitro
KR101896803B9 (ko) 인간 만능줄기세포로부터 중간엽 줄기세포로의 분화 유도 생산율을 증가시키는 방법 및 이에 의해 생성된 중간엽 줄기세포
PH12014501383A1 (en) Induced pluripotent stem cells prepared from human kidney-derived cells
WO2013188407A3 (fr) Procédé pour la différenciation in vitro de progéniteurs de motoneurones (mnps) à partir de cellules souches pluripotentes induites humaines, et cryopréservation de mnps
EP3652200A4 (fr) Induction de cellules progénitrices neurales, de cellules progénitrices d&#39;oligodendrocytes et d&#39;oligodendrocytes par différenciation de cellules souches à l&#39;aide de facteurs de transcription de points de repère
EP3194573A4 (fr) Cellules souches pluripotentes de mammifère, des procédés pour leur production et leurs utilisations
WO2014146057A3 (fr) Cellules souches mésenchymateuses
WO2012058291A3 (fr) Procédés et compositions de différenciation de cellules souches embryonnaires

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2928639

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12016500782

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2016527338

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/005657

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014342995

Country of ref document: AU

Date of ref document: 20140521

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016009399

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: IDP00201603594

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 20167014409

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016121409

Country of ref document: RU

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014857034

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014857034

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14857034

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016009399

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160427